169 related articles for article (PubMed ID: 35920929)
1. CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vδ2
Dong T; Wu N; Gao H; Liang S; Dong X; Zhao T; Jiang Q; Liu J
Ann Hematol; 2022 Oct; 101(10):2195-2208. PubMed ID: 35920929
[TBL] [Abstract][Full Text] [Related]
2. STAT5 is essential for inducing the suppressive subset and attenuate cytotoxicity of Vδ2
Cheng C; Liang S; Yue K; Wu N; Li Z; Dong T; Dong X; Ling M; Jiang Q; Liu J; Huang XJ
Cancer Lett; 2024 Apr; 587():216730. PubMed ID: 38360140
[TBL] [Abstract][Full Text] [Related]
3. Identification of the immunosuppressive effect of γδ T cells correlated to bone morphogenetic protein 2 in acute myeloid leukemia.
Liang S; Dong T; Yue K; Gao H; Wu N; Liu R; Chang Y; Hao L; Hu L; Zhao T; Jiang Q; Huang XJ; Liu J
Front Immunol; 2022; 13():1009709. PubMed ID: 36325350
[TBL] [Abstract][Full Text] [Related]
4. BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia.
Benyamine A; Le Roy A; Mamessier E; Gertner-Dardenne J; Castanier C; Orlanducci F; Pouyet L; Goubard A; Collette Y; Vey N; Scotet E; Castellano R; Olive D
Oncoimmunology; 2016; 5(10):e1146843. PubMed ID: 27853633
[TBL] [Abstract][Full Text] [Related]
5. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.
Wu K; Feng J; Xiu Y; Li Z; Lin Z; Zhao H; Zeng H; Xia W; Yu L; Xu B
Int Immunopharmacol; 2020 Mar; 80():106122. PubMed ID: 31955066
[TBL] [Abstract][Full Text] [Related]
6. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.
Driouk L; Gicobi JK; Kamihara Y; Rutherford K; Dranoff G; Ritz J; Baumeister SHC
Front Immunol; 2020; 11():580328. PubMed ID: 33384686
[TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia.
Trad R; Warda W; Alcazer V; Neto da Rocha M; Berceanu A; Nicod C; Haderbache R; Roussel X; Desbrosses Y; Daguindau E; Renosi F; Roumier C; Bouquet L; Biichle S; Guiot M; Seffar E; Caillot D; Depil S; Robinet E; Salma Y; Deconinck E; Deschamps M; Ferrand C
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35803613
[TBL] [Abstract][Full Text] [Related]
9. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
10. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
[TBL] [Abstract][Full Text] [Related]
11. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
12. High
Kong X; Zheng J; Liu X; Wang W; Jiang X; Chen J; Lai J; Jin Z; Wu X
Front Immunol; 2022; 13():823352. PubMed ID: 35222403
[TBL] [Abstract][Full Text] [Related]
13. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
14. Gamma delta T cells in acute myeloid leukemia: biology and emerging therapeutic strategies.
Rao A; Agrawal A; Borthakur G; Battula VL; Maiti A
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417915
[TBL] [Abstract][Full Text] [Related]
15. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
[TBL] [Abstract][Full Text] [Related]
16. [Current Status and New Drugs Progress in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia--Review].
Li WF; Zhou JB; Zhao YH; Yu HJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1907-1911. PubMed ID: 36476924
[TBL] [Abstract][Full Text] [Related]
17. Activation of V gamma 9V delta 2 T cells by NKG2D.
Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia.
Goswami M; Gui G; Dillon LW; Lindblad KE; Thompson J; Valdez J; Kim DY; Ghannam JY; Oetjen KA; Destefano CB; Smith DM; Tekleab H; Li Y; Dagur P; Hughes T; Marté JL; Del Rivero J; Klubo-Gwiezdzinksa J; Gulley JL; Calvo KR; Lai C; Hourigan CS
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017151
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms.
Lee J; Minden MD; Chen WC; Streck E; Chen B; Kang H; Arruda A; Ly D; Der SD; Kang S; Achita P; D'Souza C; Li Y; Childs RW; Dick JE; Zhang L
Clin Cancer Res; 2018 Jan; 24(2):370-382. PubMed ID: 29074605
[No Abstract] [Full Text] [Related]
20. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
